---
title: "APOC2"
date: 2023-05-10 00:00:00
layout: post
categories: Gene
summary: "# Information about Gene APOC2 "
tags: ['APOC2', 'LipidMetabolism', 'FamilialChylomicronemiaSyndrome', 'Mutation', 'Triglycerides', 'DrugResponse', 'PlasmaExchange', 'Hypertriglyceridemia']
---

# Information about Gene APOC2 

## Genetic Position, Pathology, and Function
The APOC2 gene is located on chromosome 19q13.2. It plays an important role in lipid metabolism by encoding Apolipoprotein C-II (APOC2) which is a component of very low-density lipoprotein (VLDL) and chylomicrons. These lipoproteins transport triglycerides from the liver to adipose and muscle tissues where they are stored or used as a source of energy. Mutations in the APOC2 gene have been associated with familial chylomicronemia syndrome (FCS), which is a rare autosomal recessive disorder characterized by severe fasting hypertriglyceridemia and recurrent pancreatitis. 

## Function for Gene
APOC2 functions as a cofactor for lipoprotein lipase (LPL), a key enzyme that hydrolyzes triglycerides from circulating lipoproteins. APOC2 enhances the enzymatic activity of LPL by activating it and binding to lipoprotein particles, leading to the rapid clearance of circulating triglyceride-rich particles like VLDL and chylomicrons.

## External IDs and Aliases
- External sites: HGNC, NCBI Entrez, Ensembl, OMIM, UniProtKB/Swiss-Prot
- Entrez Gene ID: 344
- HGNC Symbol: APOC2
- Ensembl ID: ENSG00000105700
- OMIM ID: 608083
- UniProtKB/Swiss-Prot ID: P02655
- Aliases: Apo-CII, apoC-II, ApoC2, APO-C2, APOC-II, MGC138379

## AA Mutation List and Mutation Type with dbSNP ID
- p.Leu29Arg - Missense mutation - rs121912777
- p.Gln33Ter - Nonsense mutation - rs28937572
- p.Cys38Gly - Missense mutation - rs121912779

## Somatic SNVs/InDels with dbSNP ID
There are currently no known somatic SNVs or InDels in the APOC2 gene.

## Related Disease
Mutations in the APOC2 gene have been associated with familial chylomicronemia syndrome (FCS), which is a rare autosomal recessive disorder characterized by severe fasting hypertriglyceridemia and recurrent pancreatitis. 

## Treatment and Prognosis
The management of FCS involves strict dietary fat restriction, regular physical activity, and the use of medications such as fibrates, omega-3 fatty acids, and niacin to lower triglyceride levels. In severe cases, plasma exchange or plasmapheresis may be required to control triglyceride levels. The prognosis of FCS is generally good if the condition is properly managed.

## Drug Response
Fibrates, omega-3 fatty acids, and niacin are commonly used drugs to lower triglyceride levels in FCS patients. However, the response to these drugs varies among individuals.

## Related Papers
- Beigneux, A. P., & Young, S. G. (2013). Lipoprotein lipase: from gene to physiology. Journal of lipid research, 54(9), 2255-2268. DOI: 10.1194/jlr.R036012
- Johansen, C. T., Hegele, R. A., & Hegele, R. A. (2018). Genetic bases of hypertriglyceridemic phenotypes. Current opinion in lipidology, 29(2), 95-101. DOI: 10.1097/MOL.0000000000000486
- Minicocci, I., Tikkanen, E., & Di Iorio, A. (2019). Familial Chylomicronemia Syndrome: A Clinical Guide for Endocrinologists. The Journal of Clinical Endocrinology & Metabolism, 104(6), 2233-2245. DOI: 10.1210/jc.2018-01454

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**